|
|
Article: Findings in type 2 diabetes reported from Actelion Pharmaceuticals Ltd., Department of Clinical Pharmacology.(Clinical report)
- Article from:
- Diabetes Week
- Article date:
- November 9, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Fresh data on type 2 diabetes are presented in the report 'Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus.' In this recent report, researchers in Allschwil, Switzerland conducted a study "To investigate the effects of palosuran, a nonpeptidic, potent and selective antagonist of the urotensin-II receptor, on insulin and glucose regulation in 20 diet-treated patients with Type 2 diabetes mellitus in a double-blind, placebo-controlled, randomized, crossover, proof-of-concept study. After 4 weeks' oral treatment with 125 mg palosuran or placebo b.i.d.,effects on insulin secretion ...
Related newspaper, magazine, and journal articles:
|
|
Article: Study findings from Actelion Pharmaceuticals Ltd. ...
Biotech Week;
October 15, 2008 ;
700+ words
... ... wrote C. Mangold and colleagues, Actelion Pharmaceuticals Ltd.. The researchers concluded ... information, contact C. Mangold, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH ... Keywords: Switzerland, Allschwil, Actelion Pharmaceuticals Ltd., Biotechnology Business ...
|
|